In a bid to advance from yeast-two-hybrid-based target provider to lead generator, Hybrigenics of Paris said last week that it had acquired ailing cancer signal transduction company Semaia Pharmaceuticals in an all-stock deal.
In a bid to advance from yeast-two-hybrid-based target provider to lead generator, Hybrigenics of Paris said last week that it had acquired ailing cancer signal transduction company Semaia Pharmaceuticals in an all-stock deal.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.